(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of 2.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Puma Biotechnology's revenue in 2024 is $226,628,000.On average, 2 Wall Street analysts forecast PBYI's revenue for 2024 to be $10,587,462,798, with the lowest PBYI revenue forecast at $10,586,498,021, and the highest PBYI revenue forecast at $10,588,427,575. On average, 3 Wall Street analysts forecast PBYI's revenue for 2025 to be $11,511,526,209, with the lowest PBYI revenue forecast at $11,340,953,635, and the highest PBYI revenue forecast at $11,770,279,400.
In 2026, PBYI is forecast to generate $12,042,828,903 in revenue, with the lowest revenue forecast at $12,040,416,960 and the highest revenue forecast at $12,045,240,845.